GlassScriptPhysician profile
Tina S-T Chen
NPI 1073759627
$3,241.75
in general payments reported to CMS, 2019-2025
19 companies · $1,274 in 2025
The $1,274 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $460 · 2021: $134 · 2022: $45.96 · 2023: $153 · 2024: $1,175 · 2025: $1,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,387 · Education: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,387.16 |
| Education | $214.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $446.36 | 2022-2025 | |
| Janssen Biotech, INC. | $394.95 | 2024-2025 | Tremfya |
| Genzyme Corporation | $371.81 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $367.37 | 2019-2025 | Dupixent, Libtayo |
| Abbvie INC. | $296.12 | 2024-2025 | |
| Incyte Corporation | $284.83 | 2023-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $209.27 | 2019 | |
| Ucb, INC. | $176.53 | 2024-2025 | Bimzelx |
| Regeneron Pharmaceuticals, INC. | $126.19 | 2019 | |
| Verrica Pharmaceuticals INC. | $92.72 | 2023-2025 | Ycanth |
| Leo Pharma INC. | $91.67 | 2024-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $72.18 | 2025 | |
| Galderma Laboratories, L.P. | $68.03 | 2024-2025 | Nemluvio |
| Amgen INC. | $67.59 | 2024-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $55.26 | 2023-2024 | Zoryve |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.87 | 2024-2025 | Spevigo |
| Almirall LLC | $38.79 | 2019-2024 | Klisyri |
| Helsinn Therapeutics (U.S.), INC. | $16.70 | 2024 | Valchlor |
| Pierre Fabre Pharmaceuticals, INC. | $13.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tina Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.